You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Pfizer’s COVID-19 pill cuts hospitalisation/death risk by 89%

Pfizer has announced that its investigational COVID-19 antiviral medicine cut the risk of hospitalisation or death by 89% in an interim analysis of the Phase II/III EPIC-HR study.